drugset / Trial / NCT02906813

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

NCT02906813

Phase 1 Completed 9 enrolled Takeda
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to assess the relative bioavailability (BA) of 300 milligram (mg) TAK-935 tablets compared to 300 mg of TAK-935 solution and to determine the effect of food on the BA of TAK-935 300 mg tablets in healthy adult participants.

Timeline

Start
2016-09-12
Primary completion
2016-10-12
Completion
2016-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Soticlestat Small molecule 300 mg Oral

Indications

No indication recorded.